Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025837 | 0.81 | KMT2A (0.49) | MAOAMAOBNOTUMHSD17B3LMNA | |
| SCHEMBL30082660 | 0.79 | MAOA (0.41) | MAOAMAOBNOTUMHSD17B3LMNA | |
| SCHEMBL19373821 | 0.77 | ITGB2 (0.46) | LMNASMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19373819 | 0.77 | ITGB2 (0.46) | LMNASMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19373820 | 0.77 | ITGB2 (0.46) | LMNASMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL346944 | 0.73 | — | — | |
| SCHEMBL10170816 | 0.73 | OXTR (0.52) | MAOAMAOBHSD17B3LMNASMN1; SMN2 | |
| SCHEMBL30349594 | 0.73 | — | — | |
| SCHEMBL13926200 | 0.71 | KMT2A (0.36) | MAOAMAOBNOTUMHSD17B3LMNA | |
| SCHEMBL28675786 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859005-B1 | NOVEL MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-04-27 | — | — | EP | disclosed |
| US-8124249-B2 | Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers | MERCK PATENT GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124249-B2 | Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers | MERCK PATENT GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | OR10J3, EML4, TYR | MAOA 298/4885MAOB 438/4885NOTUM 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.